Eldelumab (alternative identifier BMS-936557[1]) is a fully human monoclonal antibody (type IgG1 kappa)[2] that targets chemokine (C-X-C motif) ligand 10 (CXCL10)/Interferon-γ-inducible protein-10 (IP-10)[2][1] designed for the treatment of Crohn's disease and ulcerative colitis.[3]

Eldelumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetCXCL10/IP-10
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6502H10024N1736O2026S48
Molar mass146468.72 g·mol−1

This drug was developed by Bristol-Myers Squibb and Medarex.[4]

References

edit
  1. ^ a b Sandborn WJ, Colombel JF, Ghosh S, Sands BE, Dryden G, Hébuterne X, et al. (April 2016). "Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study". Journal of Crohn's & Colitis. 10 (4): 418–28. doi:10.1093/ecco-jcc/jjv224. PMC 4946756. PMID 26721935.
  2. ^ a b "Anti-CXCL10 Therapeutic Antibody (eldelumab) - Creative Biolabs". www.creativebiolabs.net. Retrieved 2017-03-24.
  3. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Eldelumab, American Medical Association.
  4. ^ "Eldelumab". AdisInsight. Springer Nature Switzerland AG.